Sa1753 - Tofacitinib Achieves Symptomatic Improvement within 3 Days in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior Tumour Necrosis Factor Inhibitor Treatment Status: Results from Octave Induction 1 & 2